'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
01
Med-Fine FamilyFinancing Progress
1. SuperMenisCompleted Pre-A Round Financing of Tens of Millions of Yuan, the World's First Artificial Meniscus Technology Platform by SuperMenis to Be Launched SoonRecently, SuperMenis (Beijing) Pharmaceutical Technology Co., Ltd. announced that it has completed a Pre-A round of financing worth tens of millions of yuan, invested by ClearSource Venture Capital. This round of financing will mainly be used for the clinical development of the company's core product, the artificial meniscus implant, and the commercialization of the innovative meniscus suture device. The company’s additional round of financing is also currently open for investment. Changhai Capital continues to serve as the exclusive financial advisor for the company’s financing.Learn More
Med-Fine FamilyResearch Progress
1. Danqing PharmaceuticalsSecond DDR Therapy IND Application Approved by FDAOn April 11, 2025, Danatlas Pharmaceuticals announced that the IND application for its self-developed DNA polymerase theta (POLQ) inhibitor DAT-1604 has been approved by the U.S. Food and Drug Administration (FDA). Together with the previously approved PARG inhibitor DAT-2645 for clinical research, the company now has two DDR (DNA Damage Repair) therapies approved to enter clinical trials. This marks a critical step for Danatlas Pharmaceuticals in addressing unmet clinical needs for patients with breast cancer and gynecological cancers worldwide.Learn More2. Guo Ke Sai FuHebei Pharmaceutical Technology Co., Ltd. Successfully Passes OECD GLP Re-certificationSAF Pharmaceutical Group's subsidiary, Guoke SAF Hebei Pharmaceutical Technology Co., Ltd., successfully passed the OECD GLP certification re-inspection on April 6, 2025! Following the initial certification, this marks another high-standard validation for our company in quality management and international compliance, signifying our continued commitment to upholding the global credibility of research data with excellence!Learn More3. The world's first engineered exosome to receive INCI naming,Yinuo MicroLeading a New Era of International Cosmetic IngredientsSuperMenis, a subsidiary of ImmunoViro Therapeutics, recently announced that its self-developed engineered exosome product MVR-EX103 for damaged skin repair has successfully passed the review of the International Nomenclature Committee (INC) and has been officially granted the International Nomenclature of Cosmetic Ingredients (INCI) name "Exosome".Learn More4. Ansong TechnologyNew Evidence Added, Officially Ushering in a New Era of DentistryOn April 23, 2025, Ansong Technology Dental received another piece of good news as its dental implant system was successfully approved for market launch. This marks that Ansong Technology's products in the dental implant field have been initially perfected, and the Ansong Dental era is about to begin.Learn More5. Aikema MedicalCardiac Pulse Ablation System Receives NMPA Approval for Market LaunchOn April 29, 2025, the PFA cardiac pulse ablation system independently developed by AccuPulse Medical was officially approved by the China National Medical Products Administration (NMPA) for marketing in China!Learn More6. AikemaAccuQuest Transseptal Needle Officially ApprovedAccuPulse Medical's self-developed transseptal needle (AccuQuest® Transseptal Needle) has officially passed the approval of the National Medical Products Administration (NMPA).Learn More7.FuzhouChina GeneSuccessfully Passed CNAS Laboratory AccreditationIn April 2025, Fuzhou Zhongke Gene Technology Co., Ltd. successfully passed the evaluation by the China National Accreditation Service for Conformity Assessment (hereinafter referred to as "CNAS") and was awarded the laboratory accreditation certificate, with the registration number CNAS L23072.Learn More8.ChinaGeneBeijing Lab Successfully Passes CNAS Proficiency Testing Provider Accreditation Surveillance Review + Expansion ReviewOn March 21, 2025, the China National Accreditation Service for Conformity Assessment (CNAS) officially issued the surveillance review + scope expansion review accreditation decision letter to Beijing Zhongke Gene Technology Co., Ltd. Beijing Laboratory as a proficiency testing provider. After evaluation, the laboratory’s accreditation status as a proficiency testing provider was maintained and its accredited scope was expanded. The updated scope of proficiency testing was officially announced on April 11, 2025.Learn More03
Med-Fine FamilyBusiness Breakthrough
1. Execlim BiotechHeavyweight Pipeline Debuts at Sci-Tech Innovation Investment Service Special RoadshowOn April 3, 2025, against the backdrop of the accelerating industrialization of global bispecific antibody drug development and the ongoing wave of Chinese innovative drugs "going global," Guangzhou Exceed BioTechnology Co., Ltd. showcased its key pipeline at the "Bispecific Antibody Science and Finance Forum & Exceed BioTechnology Project Roadshow" held in Guangzhou Science City. At the event, Dr. Wenjun Zhang, founder and CEO of Exceed BioTechnology, presented the technological advantages of the company's self-developed ExMab® bispecific antibody platform in developing multispecific antibodies, breakthrough results from multiple ongoing clinical projects, and innovative T-cell engagers (TCE) including shielding peptide technology. In-depth discussions and collaboration talks on project capital pathways and clinical development were conducted with over ten investment institutions and industry experts.Learn More2. Zhonuo BioTo Be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingHangzhou, China and Boston, Massachusetts, USA, April 5, 2024 -- Ranok Bio, a clinical-stage biopharmaceutical company developing a novel approach to targeted protein degradation for cancer treatment, today announced that it will participate in the American Association for Cancer Research (AACR) Annual Meeting held in San Diego, California, USA from April 5 to 10, 2024. The company will present a poster showcasing the mechanism of action of its CHAMP (Chaperone-Mediated Protein Degradation) technology for tumor targeting.Learn More3. Using "Convection-Enhanced Delivery" for the treatment of malignant gliomas,Enovir MedicineOncolytic ProductsMVR-C5252Clinical Data UnveiledAACR 2025US Time2025Year4Month25Date4Month30During the period, Enovir Pharmaceuticals participated in the American Association for Cancer Research (AACR) The herpes oncolytic product for malignant glioma was first released in the form of a poster at the annual meeting.MVR-C5252Clinical research results.Learn More
Med-Fine Family Business Cooperation
1. Orange Sail PharmaceuticalsFirst Dual-Antibody Achieves Global Licensing CollaborationShanghai, China/Boston, USA, April 18, 2025 — VelaVigo, an innovative biotechnology company focused on the research and development of multispecific antibodies and antibody-drug conjugates (ADCs), announced that it has entered into a global exclusive licensing agreement with Ollin Biosciences in the United States for its self-developed first-in-class (FIC) bispecific antibody drug VBS-102. According to the agreement, Ollin Biosciences will obtain the rights to develop, manufacture, and commercialize the drug globally outside of Greater China, while VelaVigo will retain the rights in Greater China.Learn MoreMed-Fine FamilyIndustry Honors
1.Dagene BioCEODr. Zou Lihui Honored onIn Vivo 2025Annual Rising Leader List
2.Kehui Zhiyao Rated as KPMG China Biotech Innovation Leader50Strong
3.Ansong Technology Honored with "2025"Global Orthopedic Technology Innovation Award"
4.Ensheng Medical Successfully Shortlisted in "China High-Quality Medical Device Export Selection Guide"(2025》Representative Product Cases
5.Ding Xiaoxiong from Sinoway Medical was rated“Beijing Model Worker”Title
6.ZhuoDao Medical®Wang Daoyu Honored with2025Outstanding Typical Example of Pudong Excellent Youth Leadership Action
7.SuperMenis Honored with2025"Excellent Unicorn Award" at the Greater Bay Area High-Quality Development Conference on Medical and Elderly Care Technology
8.West Lake Omicron Ranks Again on the "Hangzhou Soon-to-be-Unicorn Enterprises" List
9.West Lake Omics Selected as One of the Top Ten "Hidden Dragon" Enterprises in West Lake District
